Genitourinary Cancer Clinical Trials

8 trials identified.

Patierno: Genomics of Prostate Cancer
Principal Investigator: Patierno, Steven
Protocol Number: PRO00053535

Age Group: Adult
Scope: National

Phase: N/A
Disease Site: Other Urinary; Prostate

Contact: DCI Clinical Research Team, Genitourinary Oncology
Email:

What is the Condition Being Studied?
Prostate Cancer
What is the Purpose of this Study?
We are doing this study to learn more about the differences in prostate tumors between African Americans and Caucasians who have prostate cancer by looking at the genetic materials (DNA and RNA) in tumor tissue. 
Who Can Participate in the Study?
Adult patients with suspected or proven prostate cancer who are having a prostatectomy.
What is Involved?
If you choose to join this study, we will will collect tissue and blood at the time of your planned prostate surgery. 
Participating Institutions:
  • Duke University Health System : Genitourinary Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

STARTAR
Principal Investigator: Zhang, Tian
Protocol Number: PRO00080868

Age Group: Adult
Scope: National

Phase: II (Cancer Control)
Disease Site: Prostate

Contact: DCI Clinical Research Team, Genitourinary Oncology
Email:

What is the Condition Being Studied?
Prostate cancer with a rising PSA after prostatectomy
What is the Purpose of this Study?
We are doing this study to see if adding the study drugs apalutamide and docetaxel chemotherapy to a standard treatment for prostate cancer is more effective than the standard treatment alone.
Who Can Participate in the Study?
Patients with prostate cancer who have had a prostatectomy and whose PSA has started to rise after surgery. 
What is Involved?
If you choose to join this study, you will:

Enter a screening period that includes a physical exam, imaging scans, blood draws, and quality-of-life surveys. 

Once you've completed the screening period, you will 
- Receive the study drugs apalutamide and docetaxel in addition to standard-of-care androgen deprivation therapy (ADT) and radiation therapy over a period of 36 weeks. 
- Return to clinic at least every four weeks for exams, surveys and other procedures  

- Once you finish the study treatment, you will have follow-up visits every 3 months for 3 years
Participating Institutions:
  • Duke Cancer Center Cary : Genitourinary Oncology DCI Clinical Research Team
  • Duke University Health System : Genitourinary Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK NEPC)
Principal Investigator: Armstrong, Andrew
Protocol Number: PRO00080869

Age Group: Adult
Scope: Local

Phase: II (Cancer Control)
Disease Site: Prostate

Contact: DCI Clinical Research Team, Genitourinary Oncology
Email:

What is the Condition Being Studied?
Neuroendocrine prostate cancer
What is the Purpose of this Study?
We are doing this study to learn if it is safe and effective to give men with neuroendocrine prostate cancer avelumab.
Who Can Participate in the Study?
Adult males who have been diagnosed with neuroendocrine-like prostate cancer that have not been taking PD-1 inhibitors and/or 2 inhibitors, CTLA-4 inhibitors.
What is Involved?
If you join the study, you will have a screening period that includes a physical exam, imaging scans, blood draws, and collection of archival tumor tissue. 
After screening, you will:
- Come to the clinic to receive the study drug avelumab by IV infusion every 2 weeks.   
- Have medical exams, answer questions about any medications or adverse events, have routine imaging scans, have blood drawn for routine tests and research tests, and complete quality of life questionnaires.   
- Be asked for permission to have a tumor biopsy and donate some tissue to research when your cancer worsens.   
- Come to the clinic 28 days after the last dose of avelumab and then be followed every 3 months for up to 3 years.
Participating Institutions:
  • Duke University Health System : Genitourinary Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

GALAHAD: Niraparib for Prostate Cancer
Principal Investigator: George, Daniel
Protocol Number: PRO00081275

Age Group: Adult
Scope: National

Phase: II (Cancer Control)
Disease Site: Prostate

Contact: DCI Clinical Research Team, Genitourinary Oncology
Email:

What is the Condition Being Studied?
Advanced prostate cancer with a particular type of genetic mutation.  
What is the Purpose of this Study?
We are doing this study to see if niraparib is safe and effective for men who have advanced prostate cancer.
Who Can Participate in the Study?
Adult males who have prostate cancer with a particular type of genetic marker.
What is Involved?
If you agree to join this study, you will:
- Have a pre-screening period during which your tumor tissue and blood will be analyzed to see if your cancer has a mutation that may make it susceptible to niraparib.    

After pre-screening, you will:  
- Receive the study drug niraparib which you will take by mouth  
- Come to clinic every 2 weeks for the first 4 visits and every 12 weeks thereafter.    
- At each visit, you will have tests including labs and see a provider and study nurse.    
- Have imaging done every 8-12 weeks.     

You will receive the study drug (niraparib) as long as you are tolerating it
Participating Institutions:
  • Duke University Health System : Genitourinary Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

ECOG-ACRIN EA8143 (Renal Cell Carcinoma)
Principal Investigator: Crawford, Jeffrey
Protocol Number: PRO00082493

Age Group: Adult
Scope: National

Phase: III (Cancer Control)
Disease Site: Kidney

Contact: DCI Clinical Research Team, Genitourinary Oncology
Email:

What is the Condition Being Studied?
Kidney Cancer (Renal Cell Carcinoma)
What is the Purpose of this Study?
We are doing this study to see if the study drug Nivolumab taken before and after surgery for kidney cancer is better, the same, or worse than the standard follow-up after having had surgery for kidney cancer. 
Who Can Participate in the Study?
Adults with kidney cancer who:
- Have no prior therapy for the kidney cancer
- Have no autoimmune or liver disease
- Are not pregnant or nursing
What is Involved?
If you choose to join this study, you will: 
- Be randomized (like a flip of a coin) get either:
-- Group 1: The study drug nivolumab by an IV through your vein before and after surgery once a month for a total of 10 doses
-- Group 2: Surgery followed by observation
- Have CT or MRI scans to monitor your status for up to 6 years 
- Have clinic visits every 6 months for 2-3 years and then  yearly for 4-5 years
Participating Institutions:
  • Duke University Health System : Genitourinary Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

NRG-GU002 for Prostate Cancer
Principal Investigator: Lee, William
Protocol Number: PRO00083088

Age Group: Adult
Scope: National

Phase: II/III (Cancer Control)
Disease Site: Prostate

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Prostate cancer which has been surgically removed
What is the Purpose of this Study?
We are doing this study to compare the effects of using docetaxel along with the radiation therapy and hormone suppression therapy to using radiation and hormone suppression therapy alone in men with a high chance of prostate cancer coming back after surgically removing the prostate.
Who Can Participate in the Study?
Adult men who have prostate cancer and the prostate has been surgically removed:
- are 18 years or older
What is Involved?
If you agree to be in this study you will:
- Be randomly assigned (put into one of two groups by chance like a flip of a coin) and receive either:
Group 1 - continue to receive hormone suppression therapy and will get the usual radiation therapy used for prostate cancer
Group 2 - continue to receive hormone suppression therapy and get the usual radiation therapy used for prostate cancer followed by 6 doses of the chemotherapy drug docetaxel.
 - Receive hormone suppression therapy for a total of 6 months
 - See your doctors every 3 months for 2 years, then every 6 months for 3 years, and then yearly.
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

Alliance A031501 (Bladder Cancer)
Principal Investigator: Crawford, Jeffrey
Protocol Number: PRO00089733

Age Group: Adult
Scope: National

Phase: III (Cancer Control)
Disease Site: Urinary Bladder

Contact: DCI Clinical Research Team, Genitourinary Oncology
Email:

What is the Condition Being Studied?
Bladder Cancer 
What is the Purpose of this Study?
We are doing this study to find out if the study drug MK-3475 (pembrolizumab) is better, the same, or worse than the usual approach after surgery to remove muscle-invasive bladder cancer. 
Who Can Participate in the Study?
Adults who:
- Have recently had their bladder removed
- Have no active autoimmune disease
- Are not pregnant or nursing
What is Involved?
If you choose to join this study, you will:
- Be randomized (put into one of two groups by chance like the flip of a coin) and get either:
-- Group 1: study drug MK-3475 (pembrolizumab) by intravenous infusion once every 3 weeks for one year
-- Group 2: no study drug but followed with clinic visits every 6 weeks for one year
- Get a CT or MRI scans every 12 weeks for 2 years and then yearly for up to 5 years 
Participating Institutions:
  • Duke University Health System : Genitourinary Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

MK-7123 Study for Selected Advanced/Metastatic Solid Tumors
Principal Investigator: Armstrong, Andrew
Protocol Number: PRO00092175

Age Group:
Scope:

Phase: II
Disease Site: Other

Contact: DCI Clinical Research Team, Phase I Clinical Trials Office
Email:

What is the Condition Being Studied?
Non-small cell lung cancer, Prostate Cancer or Colorectal Cancer
What is the Purpose of this Study?
We are doing this study to see how Navarixin (MK-7123) given with pembrolizumab (MK-3475) works in your body and against your cancer.
Who Can Participate in the Study?
Adults who:
- Have been diagnosed with Non-small cell lung cancer, Prostate Cancer or Colorectal Cancer
-- Non-small cell lung cancer patients must have Stage IV disease and have progressed on PD-1 treatment
-- Prostate Cancer patients must have progressed on recent treatment and on at least one second generation anti-androgen therapy
-- Colorectal Cancer patients must have locally advanced unremovable or metastatic Stage IV disease and been treated with standard therapies
What is Involved?
If you choose to be in this study, you will:
- Be randomly assigned (like the flip of a coin) to one of two groups:
-- Group A: Take 30 mg Navarixin by mouth daily and Pembrolizumab into your vein every 3 weeks
-- Group B: Take 100 mg Navarixin by mouth daily and Pembrolizumab into your vein every 3 weeks
- Provide a prior tissue sample or fresh tumor biopsy before starting the study drug
- Provide multiple blood and urine samples during the study
- Have a series of tests and scans (Computerized tomography (CT) and/or Magnetic resonance imaging (MRI)) at the study center
- Take the study drug for about 2 years and then enter the follow-up period

Participating Institutions:
  • Duke Cancer Center Cary : Phase I Clinical Trials Office DCI Clinical Research Team
  • Duke Center for Living/Sarah Stedman Nutrition : Phase I Clinical Trials Office DCI Clinical Research Team
  • Duke Primary Care : Phase I Clinical Trials Office DCI Clinical Research Team
  • Duke Private Diagnostic Clinic (PDC) : Phase I Clinical Trials Office DCI Clinical Research Team
  • Duke Raleigh Hospital : Phase I Clinical Trials Office DCI Clinical Research Team
  • Duke Regional Hospital : Phase I Clinical Trials Office DCI Clinical Research Team
  • Duke University Health System : Phase I Clinical Trials Office DCI Clinical Research Team
  • Duke Women's Cancer Care Raleigh (Macon Pond) : Phase I Clinical Trials Office DCI Clinical Research Team
  • Johnston Health (Smithfield) : Phase I Clinical Trials Office DCI Clinical Research Team
  • Maria Parham Health (Henderson) : Phase I Clinical Trials Office DCI Clinical Research Team
  • Scotland Health Care System (Laurinburg) : Phase I Clinical Trials Office DCI Clinical Research Team
  • Southeastern Regional Medical Center (Lumberton) : Phase I Clinical Trials Office DCI Clinical Research Team
View this trial at ClinicalTrials.gov